Annual Review of Amitiza® Fiscal Year 2008

Oklahoma Health Care Authority January 2009

Amitiza®

- Locally acting chloride channel activator.
- For treatment of chronic idiopathic constipation in the adult population.
- April 29, 2008- The FDA approved a new indication for Amitiza for the treatment of irritable bowel syndrome with constipation (IBS-C) in women aged 18 years and older. The recommended dose is one 8mcg capsule taken twice daily with food and water.

Prior Authorization Category for FY '08

Criteria to Prior Authorize Amitiza®:

- Chronic Idiopathic Constipation in males and females 18 years of age and older who meet the following criteria, or IBS-Constipation predominant in females 18 years of age or older:
 - Have documentation that therapies that cause constipation, used for other disease states, have been discontinued (excluding opioid pain medications for cancer patients).
 - b. Documented and updated Colon Screening. (>50 years of age)
- 2. Hydration and treatment attempts with a minimum of three alternate products must be documented.
- 3. Initial approval for 12 weeks of therapy. An additional year approval may be granted if physician documents client is responding well to treatment.
- 4. Quantity limit of 100 units for a 50 day supply.

Utilization

From July 1, 2007 to June 30, 2008 a total of 57 members received Amitiza® through the SoonerCare program.

| Product | # of Claims | Total Units | Total Days | Units/ Day | Total Cost | Total Members | Per Diem |
|----------------------------|----------------|----------------|---------------|---------------|-------------|------------------|-------------|
| Amitiza [®] 24mcg | 202 | 11,324 | 6,142 | 1.84 | \$35,539.14 | 57 | \$5.79 |

| Total Cost FY '08 | \$35,539.14 |
|----------------------|-------------|
| Total Cost FY '07 | \$7,720.47 |
| Total Claims FY '08 | 202 |
| Total Claims FY '07 | 47 |
| Total Members FY '08 | 57 |
| Total Members FY '07 | 25 |
| Per Diem FY '08 | \$5.79 |
| Per Diem FY '07 | \$5.47 |

Prior Authorizations

| Prior Authorizations | No. of Petitions FY07 | No. of Petitions FY08 |
|----------------------|--------------------------|--------------------------|
| Approved | 31 | 82 |
| Denied | 61 | 112 |
| Incomplete | 14 | 56 |
| Total | 106 | 250 |

Claims were reviewed to determine the age/gender of the members.

FY '08 all members

| Age | Female | Male | Totals |
|-------------|--------|------|--------|
| 0 to 9 | 0 | 0 | 0 |
| 10 to 19 | 4 | 0 | 4 |
| 20 to 34 | 13 | 4 | 17 |
| 35 to 49 | 10 | 5 | 15 |
| 50 to 64 | 14 | 2 | 16 |
| 65 to 79 | 1 | 0 | 1 |
| 80 to 94 | 0 | 1 | 1 |
| 95 and Over | 0 | 0 | 0 |
| Totals | 42 | 12 | 54* |

^{*3} members with missing age or gender codes, total of 57 members

Top 10 Prescriber Specialties

| Prescriber Specialty | Number of Claims | Total Amount Paid |
|----------------------|------------------|-------------------|
| Family Practitioner | 92 | \$14,139.47 |
| Internist | 27 | \$4,897.09 |
| General Practitioner | 20 | \$3,948.43 |
| Gastroenterologist | 19 | \$3,640.54 |
| DDSD-NFM | 13 | \$2,647.23 |
| General Surgeon | 9 | \$1,567.81 |
| General Pediatrician | 7 | \$2,235.94 |
| Physician Assistant | 6 | \$1,183.86 |
| Nephrologist | 4 | \$770.04 |
| Pulmonary Disease | 3 | \$250.62 |

Recommendations

The College of Pharmacy recommends continued monitoring at this time.